Zusammenfassung
Die Verordnungsstruktur der Psychopharmaka hat sich in den letzten 10 Jahren nochmals auffällig verändert. Im Durchschnitt haben sich die Verordnungen der Antidepressiva in der letzten Dekade fast verdoppelt mit abflachender Tendenz seit 2012.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Abbas S, Ihle P, Adler JB, Engel S, Günster C, Linder R, Lehmkuhl G, Schubert I (2016): Psychopharmaka-Verordnungen bei Kindern und Jugendlichen in Deutschland. Bundesweite Auswertung von über 4 Millionen gesetzlich Versicherten von 2004 bis 2012. Dtsch Ärztebl. 113: 396–403
Aderhold V, Weinmann S, Hägele C, Heinz A (2014): Frontale Hirnvolumenminderung durch Antipsychotika? Nervenarzt 86: 302–323
American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity (2004): Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 27: 596–601
Anderson IM (2000): Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. J Affect Disord 58: 19–36
Arroll B, Macgillivray S, Ogston S, Reid I, Sullivan F, Williams B, Crombie I (2005): Efficacy and tolerability of tricyclic antidepressants and SSRIs compared with placebo for treatment of depression in primary care: a meta-analysis. Ann Fam Med 3: 449–456
Arzneimittelkommission der deutschen Ärzteschaft (2004): Suizide und Suizidversuche unter Bupropion. Deutsches Ärzteblatt 101: A 2139–2140
Arzneimittelkommission der deutschen Ärzteschaft (2006): Hypersexualität unter Aripiprazol. Dtsch Ärztebl 103: A3518
Arzneimittelkommission der deutschen Ärzteschaft (2011): Aus der UAW-Datenbank: Abhängigkeitspotenzial unter Pregabalin (Lyrica®). Dtsch Ärztebl 108: A 183
Bachmann CJ, Lempp T, Glaeske G, Hoffmann F (2014): Antipsychotika-Verordnungen bei Kindern und Jugendlichen:Auswertung von Daten einer gesetzlichen Krankenkasse für den Zeitraum 2005–2012. Dtsch Arztebl 111: 25–34
Baghai TC, Lieb M, Möller HJ, Bschor T, Härter M, Schauenburg H (2011): Antidepressiva bei leichten depressiven Störungen. Psychiatr Prax 38: 270–273
Bauer M, Adli M, Bschor T, Pilhatsch M, Pfennig A, Sasse J, Schmid R, Lewitzka U (2010): Lithium’s emerging role in the treatment of refractory major depressive episodes: augmentation of antidepressants. Neuropsychobiology 62: 36–42
Bauer M, Grof P, Müller-Oerlinghausen B (Hsgb.) (2006): Lithium in Neuropsychiatry: The Comprehensive Guide. Informa healthcare. Oxon (UK)
Baumann P, Spies M, Möller HJ, Kasper S, Bitter I, Laux G (2016): A proposal for a psychopharmacology-pharmacotherapy catalogue of learning objectives and a curriculum in Europe. World J Biol Psychiatry. 2016 Apr 6: 1–10. [Epub ahead of print]
Bendz H, Schön S, Attman PO, Aurell M (2010): Renal failure occurs in chronic lithium treatment but is uncommon. Kidney Int 77: 219–224
Bocchetta A, Ardau R, Carta P, Ligas F, Sardu C, Pani A, Del Zompo M (2013): Duration of lithium treatment is a risk factor for reduced glomerular function: a cross-sectional study. BMC Med. 2013 Feb 11;11:33. doi:10.1186/1741-7015-11-33
Braun C, Bschor T, Franklin J, Baethge C (2016): Suicides and suicide attempts during long-term treatment with antidepressants: A meta-analysis of 29 placebo-controlled studies including 6,934 patients with major depressive disorder. Psychother Psychosom 85: 171–179
Bschor T, Adli M (2009): Therapie depressiver Erkrankungen. Dtsch Ärztebl 105: A 782–A 792
Bschor T, Hartung HD (2008): Antidepressiva Kombinationsbehandlungen. In Bschor T (Hrsg): Behandlungsmanual therapieresistenter Depressionen. Kohlhammer, Stuttgart, S. 86–101
Bschor T, Müller-Oerlinghausen B (2014): Antidepressiva verringern nicht das Risiko von Suiziden oder Suizidversuchen bei depressiven Patienten Eine Entgegnung zur Presseerklärung der Deutschen Gesellschaft für Psychiatrie, Psychotherapie, Psychosomatik und Nervenheilkunde (DGPPN). Arzneiverordnung in der Praxis 41: Heft 2, 2–4
Bschor T, Müller-Oerlinghausen B, Stoppe G, Hiemke C (2014): Neue Fakten zur Phasenprophylaxe der bipolar affektiven Erkrankung. Nervenarzt 85: 1166–1170
Cipriani A, Koesters M, Furukawa TA, Nosè M, Purgato M, Omori IM, Trespidi C, Barbui C (2012): Duloxetine versus other anti-depressive agents for depression. Cochrane Database Syst Rev. 2012 Oct 17;10:CD006533
Cipriani A, Hawton K, Stockton S, Geddes JR (2013): Lithium in the prevention of suicide in mood disorders: updated systematic review and meta-analysis. BMJ 346: f3646, doi:10.1136/bmj.f3646
Cipriani A, Rendell J, Geddes JR (2010): Olanzapine in the longterm treatment of bipolar disorder: a systematic review and meta-analysis. J Psychopharmacol 24: 1729–1738
Clark RE, Bartels SJ, Mellman TA, Peacock WJ (2002): Recent trends in antipsychotic combination therapy of schizophrenia and schizoaffective disorder: implications for state mental health policy. Schizophr Bull 28: 75–84
Coghill D, Banaschewski T, Lecendreux M, Soutullo C, Johnson M, Zuddas A, Anderson C, Civil R, Higgins N, Lyne A, Squires L (2013): European, randomized, phase 3 study of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder. Eur Neuropsychopharmacol 23: 1208–1218
Collins JC, McFarland BH (2008): Divalproex, lithium and suicide among Medicaid patients with bipolar disorder. J Affect Disord 107: 23–28
Connolly KR, Thase ME (2011): If at first you don’t succeed: a review of the evidence for antidepressant augmentation, combination and switching strategies. Drugs 71: 43–64
Coupland C, Dhiman P, Morriss R, Arthur A, Barton G, Hippisley-Cox J (2011): Antidepressant use and risk of adverse outcomes in older people: population based cohort study. BMJ 343: d4551. doi:10.1136/bmj.d4551
Coupland C, Hill T, Morriss R, Arthur A, Moore M, Hippisley-Cox J (2015): Antidepressant use and risk of suicide and attempted suicide or self harm in people aged 20 to 64: cohort study using a primary care database. BMJ 2015 Feb 18; 350: h517. doi:10.1136/bmj.h517.
Coyle CM, Laws KR (2015): The use of ketamine as an antidepressant: a systematic review and meta-analysis. Human Psychopharmacol 30: 152–163
Croissant B, Mann K (2004): Pharmakologische Rückfallprophylaxe bei Alkoholabhängigkeit. Psychoneuro 30: 30–36
Dalsgaard S, Østergaard SD, Leckman JF, Mortensen PB, Pedersen MG (2015): Mortality in children, adolescents, and adults with attention deficit hyperactivity disorder: a nationwide cohort study. Lancet 385: 2190–2196
Danielsson B, Collin J, Jonasdottir Bergman G, Borg N, Salmi P, Fastbom J (2016): Antidepressants and antipsychotics classified with torsades de pointes arrhythmia risk and mortality in older adults - a Swedish nationwide study. Br J Clin Pharmacol 81: 773–783
Davidson M, Galderisi S, Weiser M, Werbeloff N, Fleischhacker WW, Keefe RS, Boter H, Keet IP, Prelipceanu D, Rybakowski JK, Libiger J, Hummer M, Dollfus S, López-Ibor JJ, Hranov LG, Gaebel W, Peuskens J, Lindefors N, Riecher-Rössler A, Kahn RS (2009): Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-label clinical trial (EUFEST). Am J Psychiatry 166: 675–682
Dersch R, Zwernemann S, Voderholzer U (2011): Partial status epilepticus after electroconvulsive therapy and medical treatment with bupropion. Pharmacopsychiatry 44: 344–346
Deutsche Gesellschaft für Psychiatrie, Psychotherapie und Nervenheilkunde (DGPPN, Federführung) (2015): S3-Leitlinie/Nationale VersorgungsLeitlinie Unipolare Depression, 2. Auflage, AWMF-Register-Nr.: nvl-005. Internet: http://www.depression.versorgungsleitlinien.de
Deutsche Gesellschaft für Soziale Psychiatrie (DGSP) (2009): DGSP-Memorandum zur Anwendung von Antipsychotika. Soziale Psychiatrie 34: 50–51
De Zwaan M, Gruss B, Müller A, Graap H, Martin A, Glaesmer H, Hilbert A, Philipsen A (2012): The estimated prevalence and correlates of adult ADHD in a German community sample. Eur Arch Psychiatry Clin Neurosci 262: 79–86
Dittmann RW, Cardo E, Nagy P, Anderson CS, Bloomfield R, Caballero B, Higgins N, Hodgkins P, Lyne A, Civil R, Coghill D (2013): Efficacy and safety of lisdexamfetamine dimesylate and atomoxetine in the treatment of attention-deficit/hyperactivity disorder: a head-to-head, randomized, double-blind, phase IIIb study. CNS Drugs 27: 1081–1092
Fountoulakis KN, Möller HJ (2010): Efficacy of antidepressants: a re-analysis and re-interpretation of the Kirsch data. Int J Neuropsychopharmacol 14: 405–412
Fournier JC, DeRubeis RJ, Hollon SD, Dimidjian S, Amsterdam JD, Shelton RC, Fawcett J (2010): Antidepressant drug effects and depression severity: a patient-level metaanalysis. JAMA 303: 47–53
Friedmann PD (2013): Alcohol use in adults. N Engl J Med 368: 1655–1656
Frye MA, Ketter TA, Leverich GS, Huggins T, Lantz C, Denicoff KD, Post RM (2000): The increasing use of polypharmacotherapy for refractory mood disorders: 22 years of study. J Clin Psychiatry 61: 9–15
Gartlehner G, Gaynes BN, Hansen RA, Thieda P, DeVeaugh-Geiss A, Krebs EE, Moore CG, Morgan L, Lohr KN (2008): Comparative benefits and harms of second- generation antidepressants: Background paper for the American College of Physicians. Ann Int Med 149: 734–750
Geddes J, Freemantle N, Harrison P, Bebbington P (2000): Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. Brit Med J 321: 1371–1376
Geddes JR, Freemantle N, Mason J, Eccles MP, Boynton J (2001): SSRIs versus other antidepressants for depressive disorder. Update Software Ltd Oxford, The Cochrane Library—Issue 1
Gerhard T, Huybrechts K, Olfson M, Schneeweiss S, Bobo WV, Doraiswamy PM, Devanand DP, Lucas JA, Huang C, Malka ES, Levin R, Crystal S (2014): Comparative mortality risks of antipsychotic medications in community-dwelling older adults. Br J Psychiatry 205: 44–51
Gerhard T, Devanand DP, Huang C, Crystal S, Olfson M (2015): Lithium treatment and risk for dementia in adults with bipolar disorder: population-based cohort study. Brit J Psychiatry 207: 46–51
Gibbons RD, Brown CH, Hur K, Marcus SM, Baumikh DK, Erkenmann JJ (2007): Early evidence on the effects of regulators’ suicidality warnings on prescriptions and suicide in children and adolescents. Am J Psychiatry 164: 1356–1363
Goldberg TE, Gomar JJ (2009): Targeting cognition in schizophrenia research: from etiology to treatment. Am J Psychiatry 166: 631–634
Goodwin FK, Fireman B, Simon GE, Hunkeler EM, Lee J, Revicki D (2003): Suicide risk in bipolar disorder during treatment with lithium and divalproex. JAMA 290: 1467–1473
Goodwin GM, Bowden CL, Calabrese JR, Grunze H, Kasper S, White R, Greene P, Leadbetter R (2004): A pooled analysis of 2 placebo-controlled 18-month trials of lamotrigine and lithium maintenance in bipolar I disorder. J Clin Psychiatry 65: 432–441
from the International AMSP Project between 1994 and 2009. Affect Disord 136: 534–1542
Greil W, Ludwig-Mayerhofer W, Erazo N, Engel RR, Czernik A, Giedke H, Müller-Oerlinghausen B, Osterheider M, Rudolf GA, Sauer H, Tegeler J, Wetterling T (1996): Comparative efficacy of lithium and amitriptyline in the maintenance treatment of recurrent unipolar depression: a randomised study. J Affect Disord 40: 179–190
Grof P (2013): Melancholia: a distinct entity? Can J Psychiatry 58: 181–182
Grof P, Müller-Oerlinghausen B (2009): A critical appraisal of lithium’s efficacy and effectiveness: the last 60 years. Bipolar Disord 11 (Suppl 2): 10–19
Grohmann R, Engel RR, Geissler KH, Rüther E (2004): Psychotropic drug use in psychiatric inpatients: recent trends and changes over time-data from the AMSP study. Pharmacopsychiatry 37 Suppl 1: S27–38
Guaiana G, Gupta S, Chiodo D, Davies SJ, Haederle K, Koesters M (2013): Agomelatine versus other antidepressive agents for major depression. Cochrane Database Syst Rev. 2013 Dec 17; (12): CD008851
Hägg S, Bate A, Stahl M, Spigset O (2008): Associations between venous thromboembolism and antipsychotics. A study of the WHO database of adverse drug reactions. Drug Saf 31: 685–694
Hansen R, Gaynes B, Thieda P, Gartlehner G, Deveaugh-Geiss A, Krebs E, Lohr K (2008): Meta-analysis of major depressive disorder relapse and recurrence with second-generation antidepressants. Psychiatr Serv 59: 1121–1130
Hayes JF, Marston L, Walters K, Geddes JR, King M, Osborn DP (2016): Lithium vs. valproate vs. olanzapine vs. quetiapine as maintenance monotherapy for bipolar disorder: a population-based UK cohort study using electronic health records. World Psychiatry 15: 53–58
Healy D (2003): Lines of evidence on the risks of suicide with selective serotonin reuptake inhibitors. Psychother Psychosom 72: 71–79
Hegerl U, Mergl R, Quail D, Schneider E, Hundemer HP, Linden M (2012): Does pain improve earlier than mood in depressed patients with painful physical symptoms treated with duloxetine? Pharmacopsychiatry 45: 114–118
Hiemke C, Baumann P, Bergemann N, Conca A, Dietmaier O, Egberts K, Fric M, Gerlach M, Greiner C, Gründer G, Haen E, Havemann-Reinecke U, Jaquenoud Sirot E, Kirchherr H, Laux G, Lutz UC, Messer T, Müller MJ, Pfuhlmann B, Rambeck B, Riederer P, Schoppek B, Stingl J, Uhr M, Ulrich S, Waschgler R, Zernig G (2011): AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011. Pharmacopsychiatry 44: 195–235
Hwang YJ, Dixon SN, Reiss JP, Wald R, Parikh CR, Gandhi S, Shariff SZ, Pannu N, Nash DM, Rehman F, Garg AX (2014): Atypical antipsychotic drugs and the risk for acute kidney injury and other adverse outcomes in older adults: a population-based cohort study. Ann Intern Med 161: 242–248
Janhsen K, Roser P, Hoffmann K (2015): Probleme der Dauertherapie mit Benzodiazepinen und verwandten Substanzen. Dtsch Ärztebl 112: 1–7
Jans T, Warnke A (2010): Die britische NICE-Guidance zu Diagnose und Therapie der Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung (ADHS) im Kindes-, Jugend- und Erwachsenenalter. Arzneiverordnung in der Praxis. 37: 4–6
Jones PB, Barnes TR, Davies L, Dunn G, Lloyd H, Hayhurst KP, Murray RM, Markwick A, Lewis SW (2006): Randomized controlled trial of the effect on Quality of Life of secondvs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry 63: 1079–1087
Kendrick T, Chatwin J, Dowrick C, Tylee A, Morriss R, Peveler R, Leese M, McCrone P, Harris T, Moore M, Byng R, Brown G, Barthel S, Mander H, Ring A, Kelly V, Wallace V, Gabbay M, Craig T, Mann A (2009): Randomised controlled trial to determine the clinical effectiveness and cost-effectiveness of selective serotonin reuptake inhibitors plus supportive care, versus supportive care alone, for mild to moderate depression with somatic symptoms in primary care: the THREAD (THREshold for AntiDepressant response) study. Health Technol Assess 13: iii-iv, ix-xi, 1–159
Kirsch I, Deacon BJ, Huedo-Medina TB, Scoboria A, Moore TJ, Johnson BT (2008): Initial severity and antidepressant benefit: a meta-analysis of data submitted to the Food and Drug Administration. PloS Med 5: e45
KlauberJ, Günther C, Gerste B, Robra BP, Schmacke N (Hsgb) (2016): Versorgungsreport 2015/2016. Schwerpunkt: Kinder und Jugendliche. Schattauer Verlag Stuttgart 2016
Komossa K, Depping AM, Meyer M, Kissling W, Leucht S (2010): Second-generation antipsychotics for obsessive compulsive disorder. Cochrane Database Syst Rev. 2010 Dec 8; (12): CD008141
Komossa K, Rummel-Kluge C, Schmid F, Hunger H, Schwarz S, El-Sayeh HG, Kissling W, Leucht S (2009): Aripiprazole versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2009 Oct 7; (4): CD006569
Kupfer DJ, Frank E, Phillips ML (2012): Major depressive disorder: new clinical, neurobiological, and treatment perspectives. Lancet 379: 1045–1055
La Torre A, Conca A, Duffy D, Giupponi G, Pompili M, Grözinger M (2014): Sexual dysfunction related to psychotropic drugs: a critical review part II: antipsychotics. Pharmacopsychiatry 46: 201–208
Lepping P, Sambhi RS, Whittington R, Lane S, Poole R (2011): Clinical relevance of findings in trials of antipsychotics: systematic review. Br J Psychiatry 198: 341–345
Leucht S, Arbter D, Engel RR, Kissling W, Davis JM (2009a): How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials. Mol Psychiatry 14: 429–447
Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM (2009b): Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 373: 31–41
Leucht S, Wahlbeck K, Hamann J, Kissling W (2003): New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and metaanalysis. Lancet 361: 1581–1589
Lewitzka U, Bauer M, Felber W, Müller-Oerlinghausen B (2013): Suizidprophylaktische Wirkung von Lithium. Aktueller Forschungsstand und Implikationen für die Therapie affektiver Störungen Nervenarzt 84: 294–306
Lewitzka U, Severus E, Bauer R, Ritter P, Müller-Oerlinghausen B, Bauer M (2015):The suicide protective effects of lithium:more than 20 years of evidence. Int. J Bipol Dis, i.Dr.
Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK; Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators (2005): Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353: 1209–1233
Linde K, Kriston L, Rücker G, Jamil S, Schumann I, Meissner K, Sigterman K, Schneider A (2015): Efficacy and acceptability of pharmacological treatments for ndepressive disorders in primary care: a systematic review and network meta-analysis. Am Fam Med 13: 69–79
MacGillivray S, Arroll B, Hatcher S, Ogston S, Reid I, Sullivan F, Williams B, Crombie I (2003): Efficacy and tolerability of selective serotonin reuptake inhibitors compared with tricyclic antidepressants in depression treated in primary care: systematic review and meta-analysis. Brit Med J 326: 1014–1019
Macritchie KAN, Geddes MR, Scott J, Haslam DRS, Goodwin GM (2001): Valproic acid, valproate and divalproex in the maintenance treatment of bipolar disorders. Cochrane Review. In: The Cochrane Library Issue 3. Oxford, Updated Software
Maher AR, Maglione M, Bagley S, Suttorp M, Hu JH, Ewing B, Wang Z, Timmer M, Sultzer D, Shekelle PG (2011): Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: a systematic review and meta-analysis. JAMA 306: 1359–1369
Maher AR, Theodore G (2012): Summary of the comparative effectiveness review on off-label use of atypical antipsychotics. J Manag Care Pharm 18 (5 Suppl B): S1–20
McDonagh M, Peterson K, Carson S, Fu R, Thakurta S (2010): Drug Class Review: Atypical Antipsychotic Drugs. Final Update 3 Report. Portland (OR): Oregon Health & Science University; July 2010. Internet: http://www.ncbi.nlm.nih.gov/books/NBK50583/
McEvoy JP, Byerly M, Hamer RM, Dominik R, Swartz MS, Rosenheck RA, Ray N, Lamberti JS, Buckley PF, Wilkins TM, Stroup TS (2014): Effectiveness of paliperidone palmitate vs haloperidol decanoate for maintenance treatment of schizophrenia: a randomized clinical trial. JAMA 311: 1978–1987
McEvoy JP;Lieberman JA;Stroup TS;Davis SM;Meltzer HY;Rosenheck RA;Swartz MS;Perkins DO;Keefe RS;Davis CE;Severe J;Hsiao JK; CATIE Investigators (2006): Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry 163: 600–610
McGorry P, Alvarez-Jimenez M, Killackey E (2013): Antipsychotic medication during the critical period following remission from first-episode psychosis: less is more. JAMA Psychiatry 70: 898–900
McKnight RF, Adida M, Budge K, Stockton S, Goodwin GM, Geddes JR (2012): Lithium toxicity profile: a systematic review and meta-analysis. Lancet 379: 721–728
Mészáros A, Czobor P, Bálint S, Komlósi S, Simon V, Bitter I (2009): Pharmacotherapy of adult attention deficit hyperactivity disorder (ADHD): a meta-analysis. Int J Neuropsychopharmacol 12: 1137–1147
Miyamoto S, Miyake S, Jarskog LF, Fleischhacker WW, Lieberman JA (2012): Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents. Mol Psychiatry 17: 1206–1227
Molina BSG, Florey K, Hinshaw SP, Greiner, AR, Arnold E, Swanson JM, Hechtman L, Jensen PS, Vitiello B, Hoza B, Pelham WE, Elliot GR, Wells KC, Abikoff HB, Gibbons RD, Marcus S, Conners CK, Epstein JN, Greenhill LL, March JS, Newcorn JH, Severe JB, Wigal T (2007): Delinquent behavior and emerging substance use in the MTA at 36 months: Prevalence, course, and treatment effects. J Am Acad Child Adolesc Psychiatry 46: 1028–1040
Möller H-J, Volz HP, Reimann IW, Stoll KD (2001): Opipramol for the treatment of generalized anxiety disorder: a placebocontrolled trial including an alprazolam-treated group. J Clin Psychopharmacol 21: 59–65
Moncrieff J (2008): Steht die Psychiatrie zum Verkauf an? Sozialpsychiatr Informationen 38: 8–18
Moncrieff J, Kirsch I (2005): Efficacy of antidepressants in adults. BMJ 331: 155–157
MTA Cooperative Group (1999): A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Arch Gen Psychiat 56: 1073–1086
Müller-Oerlinghausen B (2011): Antidepressiva sind nur bei sehr schwerer Depression Placebo überlegen. Arzneiverordnung in der Praxis 39: 60–62
Müller-Oerlinghausen B (2012): Sind atypische Antipsychotika Mittel erster Wahl bei bipolaren Störungen? Kontra. Nervenarzt 83: 1191–1192.
National Institute for Health and Care Excellence (2014): Psychosis and schizophrenia in adults: prevention and management. Clinical guideline. Internet: nice.org.uk/guidance/cg178
Offidani E, Fava GA, Tomba E, Baldessarini RJ (2013): Excessive mood elevation and behavioral activation with antidepressant treatment of juvenile depressive and anxiety disorders: a systematic review. Psychother Psychosom 82: 132–141
Patel JK, Buckley PF, Woolson S, Hamer RM, McEvoy JP, Perkins DO, Lieberman JA, For The Cafe Investigators (2009): Metabolic profiles of second-generation antipsychotics in early psychosis: Findings from the CAFE study. Schizophr Res 111: 9–16
Qaseem A, Snow V, Denberg TD, Forciea MA, Owens DK; Clinical Efficacy Assessment Subcommittee of American College of Physicians (2008): Using second-generation antidepressants to treat depressive disorders: a clinical practice guideline from the American College of Physicians. Ann Intern Med 149: 725–733
Ray WA, Chung CP, Murray KT, Hall K, Stein CM (2009): Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med 360: 225–235
Reeves RR, Ladner ME (2010): Antidepressant-induced suicidality: an update. CNS Neurosci Ther 16: 227–234
Rosenberg PB, Drye LT, Martin BK, Frangakis C, Mintzer JE, Weintraub D, Porsteinsson AP, Schneider LS, Rabins PV, Munro CA, Meinert CL, Lyketsos CG; DIADS-2 Research Group (2010): Sertraline for the treatment of depression in Alzheimer disease. Am J Geriatr Psychiatry 18: 136–145
Rösner S, Leucht S, Lehert P, Soyka M (2008): Acamprosate supports abstinence, naltrexone prevents excessive drinking: evidence from a meta-analysis with unreported outcomes. J Psychopharmacol 22: 11–23
Sayadipour A, Mago R, Kepler CK, Chambliss RB, Certa KM, Vaccaro AR, Albert TJ, Anderson DG (2012): Antidepressants and the risk of abnormal bleeding during spinal surgery: a case-control study. Eur Spine J 21: 2070–2078
Schueler YB, Koesters M, Wieseler B, Grouven U, Kromp M, Kerekes MF, Kreis J, Kaiser T, Becker T, Weinmann S (2011): A systematic review of duloxetine and venlafaxine in major depression, including unpublished data. Acta Psychiatr Scand 123: 247–265
Schwarz MJ (2016): Therapeutic drug monitoring for individualised risk reduction in psychopharmacotherapy. Trends in Analytical Chemistry June 2016 DOI:10.1016/j.trac.2016.05.027
Shine B, McKnight RF, Geddes JR (2015): Long-term effects of lithium on renal, thyroid, and parathyroid function: a retrospective analysis of laboratory data. Lancet. 2015 May 20 [Epub ahead of print]
Sikich L, Frazier JA, McClellan J, Findling RL, Vitiello B, Ritz L, Ambler D, Puglia M, Maloney AE, Michael E, De Jong S, Slifka K, Noyes N, Hlastala S, Pierson L, McNamara NK, Delporto-Bedoya D, Anderson R, Hamer RM, Lieberman JA (2008): Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study. Am J Psychiatry 165: 1420–1431
Smith D, Dempster C, Glanville J, Freemantle N, Anderson I (2002): Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis. Br J Psychiatry 180: 396–404
Smith EG, Austin L, Kim HM, Eisen SV, Kilbourne AM, Miller DR, K, Hannemann C, Sauer BC, Valenstein M (2015): Mortality associated with lithium and valproate treatment of US Veterans Health Administration patients with mental disorders. Brit J Psychiatry 207: 55–63.
Sobanski E, Sabljic D, Alm B, Baehr C, Dittmann RW, Skopp G, Strohbeck-Kuehner P (2012): A randomized, waiting list-controlled 12-week trial of atomoxetine in adults with ADHD. Pharmacopsychiatry 45: 100–107
Song HR, Kwon YJ, Woo YS, Bahk WM (2015): Effects of mirtazapine on patients undergoing naturalistic diabetes treatment: A follow-up study extended from 6 to 12 months. J Clin Psychopharmacol 35: 730–731
Soyka M, Lieb M (2015): Recent developments in pharmacotherapy of alcoholism. Pharmacopsychiatry 48: 123–135
Spielmans GI (2008): Duloxetine does not relieve painful psychological symptoms in depression. A metaanalysis. Psychother Psychosom 77: 12–16
Spielmans GI, Berman MI, Linardatos E, Rosenlicht NZ, Perry A, Tsai AC (2013): Adjunctive atypical antipsychotic treatment for major depressive disorder: a meta-analysis of depression, quality of life, and safety outcomes. PLoS Med 10(3): e1001403
Sterke CS, Ziere G, van Beeck EF, Looman CW, van der Cammen TJ (2012): Dose-response relationship between selective serotonin re-uptake inhibitors and injurious falls: a study in nursing home residents with dementia. Br J Clin Pharmacol 73: 812–820
Storebø OJ, Ramstad E, Krogh HB, Nilausen TD, Skoog M, Holmskov M, Rosendal S, Groth C, Magnusson FL, Moreira-Maia CR, Gillies D, Buch Rasmussen K, Gauci D, Zwi M, Kirubakaran R, Forsbøl B, Simonsen E, Gluud C (2015): Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD). Cochrane Database Syst Rev. 2015 Nov 25; (11): CD009885
Stübner S, Grohmann R, von Strahlendorff I, Rüther E, Möller HJ, Müller-Oerlinghausen B, Engel R, Horvarth A, Greil W (2010): Suicidality as a rare advserse event of antidepressant medication. Report from the AMSP Multicenter Drug Surveillance Project. J Clin Psychiatry 71: 1293–1307
Tandon R, Jibson MD (2003): Efficacy of newer generation antipsychotics in the treatment of schizophrenia. Psychoneuroendocrinology 28: 9–26
Toffol E, Hätönen T, Tanskanen A, Lönnqvist J, Wahlbeck K, Joffe G, Tiihonen J, Haukka J, Partonen T (2016): Lithium is associated with decrease in all-cause and suicide mortality in high-risk bipolar patients: A nationwide registry-based prospective cohort study. J Affect Disord 183: 159–165
Tranulis C, Skalli L, Lalonde P, Nicole L, Stip E (2008): Benefits and risks of antipsychotic polypharmacy: an evidence-based review of the literature. Drug Saf 31: 7–20
Tsapakis EM, Gamie Z, Tran GT, Adshead S, Lampard A, Mantalaris A, Tsiridis E (2012): The adverse skeletal effects of selective serotonin reuptake inhibitors. Eur Psychiatry 2 7: 156–169
Tsai AC, Rosenlicht NZ, Jureidini JN, Parry PI, Spielmans GI, Healy D (2011): Aripiprazole in the maintenance treatment of bipolar disorder: a critical review of the evidence and its dissemination into the scientific literature. PLoS Med 8: e1000434
Ujeyl M, Müller-Oerlinghausen B (2012): Antidepressiva zur Behandlung der Depression bei Palliativpatienten: Eine systematische Übersicht. Schmerz 26: 523–536
Vitiello B, Correll C, van Zwieten-Boot B, Zuddas A, Parellada M, Arango C (2009): Antipsychotics in children and adolescents: increasing use, evidence for efficacy and safety concerns. Eur Neuropsychopharmacol 19: 629–635
Volz HP, Möller HJ, Reimann I, Stoll K (2000): Opipramol for the treatment of somatoform disorders. Results from a placebo-controlled trial. Eur Neuropsychopharmacol 10: 211–217
Wagstaff AJ, Ormrod D, Spencer CM (2001): Tianeptine: a review of its use in depressive disorders. CNS Drugs 15: 231–259
Walder A, Greil W, Baumann P (2009): Drug-induced Pisa syndrome under quetiapine. Prog Neuropsychopharmacol Biol Psychiatry 33: 1286–1287
Weinmann S, Read J, Aderhold V (2009): Influence of antipsychotics on mortality in schizophrenia: systematic review. Schizophr Res 113: 1–11
Wensel TM, Powe KW, Cates ME (2012): Pregabalin for the treatment of generalized anxiety disorder. Ann Pharmacother 46: 424–429
Whitaker R (2010): Anatomy of an epidemic. Magic bullets, psychiatric drugs, and the astonishing rise of mental illness in America. Crown Publishing, New York
Wolter DK (2009): Risiken von Antipsychotika im Alter, speziell bei Demenzen. Eine Übersicht. Z Gerontopsychol psychiatr 22: 17–56
Zhang J, Mathis MV, Sellers JW, Kordzakhia G, Jackson AJ, Dow A, Yang P, Fossom L, Zhu H, Patel H, Unger EF, Temple RJ (2015): The US Food and Drug Administration’s perspective on the new antidepressant vortioxetine. J Clin Psychiatry 76: 8–14
Zhou S, Chan E, Pan SQ, Huang M, Lee EJ (2004): Pharmacokinetic interactions of drugs with St John’s wort. J Psychopharmacol 18: 262–276
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Lohse, M., Müller-Oerlinghausen, B. (2016). Psychopharmaka. In: Schwabe, U., Paffrath, D. (eds) Arzneiverordnungs-Report 2016. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-50351-5_41
Download citation
DOI: https://doi.org/10.1007/978-3-662-50351-5_41
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-50350-8
Online ISBN: 978-3-662-50351-5
eBook Packages: Medicine (German Language)